U.S. Stock Insider Trading | Rockwell Pharmaceuticals Discloses 5 Company Insider Transactions on March 16

K-LinePoet · 2026-03-24T18:17:36+00:00

On March 16, 2026, Rockwell Pharmaceuticals disclosed that multiple insiders conducted stock sales on March 14, including director Strobeck Mark selling 7,333 shares. The company focuses on developing and distributing hemodialysis products and is the second-largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States.

K-LinePoet

2026-03-24 18:17:36

Abstract generation in progress

On March 16, 2026, Rockwell Medical (RMTI) disclosed five insider transactions. Director Strobeck Mark sold 7,333 shares on March 14, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 16, 2026	Executive	Chole Timothy	March 14, 2026	Sell	2,444	0.90	2,199.60
March 16, 2026	Executive	TIMMINS MEGAN C.	March 14, 2026	Sell	3,667	0.90	3,300.30
March 16, 2026	Director	Strobeck Mark	March 14, 2026	Sell	7,333	0.90	6,599.70
March 16, 2026	Executive	Hunter Heather	March 14, 2026	Sell	2,444	0.90	2,199.60
March 16, 2026	Executive	Neri Jesse	March 14, 2026	Sell	2,444	0.90	2,199.60
January 5, 2026	Executive	Hunter Heather	January 2, 2026	Sell	2,868	0.84	2,396.21
January 5, 2026	Executive	Neri Jesse	January 2, 2026	Sell	886	0.84	740.25
November 18, 2025	Director	COOPER JOHN G	November 18, 2025	Sell	5,079	0.87	4,418.73
October 8, 2025	Executive	Hunter Heather	October 1, 2025	Sell	2,868	1.19	3,412.92
October 1, 2025	Executive	Neri Jesse	October 1, 2025	Sell	886	1.19	1,054.34

[Company Information]

Rockwell Medical, Inc. was incorporated in Michigan in 1996 and relocated to Delaware in 2019. Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. It is a revenue-generating company and the second-largest supplier of acid and bicarbonate concentrate for dialysis patients in the United States. Hemodialysis is the most common treatment for end-stage kidney disease, typically performed at standalone outpatient dialysis centers, hospital outpatient clinics, specialty care facilities, or at patients’ homes. Rockwell Medical produces cGMP-compliant hemodialysis concentrates at its three facilities in Michigan, Texas, and South Carolina, totaling approximately 175,000 square feet, and produces dry acid concentrates at its Iowa facility. The company uses its own delivery trucks and third-party carriers to transport most of its dialysis concentrates and mixers to dialysis clinics across the U.S. and internationally.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.